Clinical Trial Update: UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit. [Phase 3]

View source ↗

Summary

Phase 3 trial update suggesting unfractionated heparin (UFH) is the most used anticoagulant in hemodialysis and reduces circuit clotting risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemodialysis Complication

Drugs mentioned

• Unfractionated Heparin (unfractionated heparin)

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Hemodialysis Complication | Phase 3 | Status: COMPLETED